EyePoint, Inc. (EYPT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US30233G2093
EyePoint, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 31.37 m USD |
| Operating income | -243.43 m USD |
| EBIT | -231.65 m USD |
| Net income | -231.96 m USD |
| Diluted EPS – continuing operations | -3.17 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About EyePoint, Inc.
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
More stocks
- Neptune Digital Assets Corp (NDA.V)
- DATZ WORLD HOLDINGS CORP. (BOTX)
- Abocom Systems Inc (2444.TW)
- Phunware, Inc. (PHUN)
- AEye, Inc. (LIDR)
- ABUNDIA GLOBAL IMPACT GROUP, INC. (AGIG)
- RecensMedical, Inc. (394420.KQ)
- SITE Centers Corp. (SITC)
- Royalty Management Holding Corp (RMCO)
- Nano Labs Ltd (NA)
- OS Therapies Inc (OSTX)
- Ideal Power Inc. (IPWR)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.